Company Profile

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Employees

Sector

Biotechnology & Medical Research

More about the company

Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	Feb. 29	CI
Perspective Therapeutics, Inc. entered into an asset purchase agreement to acquire Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. for $8 million.	Jan. 08	CI
International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc	20-12-28	CI
Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., and Exini Diagnostics AB Announces U.S. Food and Drug Administration Clearance for Ai-Enabled Automated Bone Scan Index in Prostate Cancer on GE Healthcare’S Xeleris Platform	20-11-13	CI
Progenics Pharmaceuticals, Inc. Announces Board Changes	20-06-22	CI
Progenics Pharmaceuticals, Inc. Announces Executive Changes	20-06-22	CI
Progenics Pharmaceuticals, Inc. Announces Executive Changes	20-06-22	CI
Progenics Pharmaceuticals, Inc. Appoints Robert J. Marshall Jr. as Treasurer	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P Composite 1500	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P 600	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P 1000	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P TMI Index	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P Global BMI Index	20-06-22	CI

PROGENICS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	20-06-22	AQ
Progenics Pharmaceuticals : Lantheus Completes Merger with Progenics	20-06-22	BU
PROGENICS PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)	20-06-17	AQ
PROGENICS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)	20-06-16	AQ
Progenics Stockholders Approve Merger with Lantheus	20-06-16	GL

Alcatel-Lucent : son support multimédia choisi en Indonésie	10-01-14
Progenics Pharm : Progenics et Wyeth Annoncent que la FDA A Homologué RELISTOR	08-04-24

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
REGENERON PHARMACEUTICALS, INC.	-0.95%	+1.93%	+39.59%	+80.35%	124B
VERTEX PHARMACEUTICALS INCORPORATED	+1.40%	+3.71%	+39.94%	+154.49%	125B
ARGENX SE	+0.41%	+0.08%	+1.50%	+77.52%	32.35B
BIONTECH SE	+17.52%	+37.20%	+8.96%	-62.28%	29.34B
BEIGENE, LTD.	+1.13%	+3.75%	-0.79%	-45.50%	21.09B
SUMMIT THERAPEUTICS INC.	+16.49%	+160.23%	+1,598.40%	+406.02%	23.13B
GENMAB A/S	+1.18%	-3.23%	-28.99%	-35.58%	16.98B
WUXI APPTEC CO., LTD.	+0.15%	+2.63%	-48.51%	-70.79%	16.02B
VAXCYTE, INC.	+1.64%	+3.96%	+124.02%	+336.25%	14.35B
Average	+4.33%	+23.11%	+192.68%	+93.39%	44.78B
Weighted average by Cap.	+2.57%	+13.68%	+118.39%	+103.11%

Progenics Pharmaceuticals, Inc. Stock

Equities

US7431871067

Biotechnology & Medical Research

Latest news: Progenics Pharmaceuticals, Inc.

Press Releases: Progenics Pharmaceuticals, Inc.

News in other languages: Progenics Pharmaceuticals, Inc.

Managers and Directors: Progenics Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Company Profile